Taxane and Carboplatin + Short-term Sintilimab
ApprovedRecruiting 0 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Triple-negative Breast Cancer
Conditions
Triple-negative Breast Cancer
Trial Timeline
Jul 1, 2023 → Dec 31, 2034
NCT ID
NCT05843292About Taxane and Carboplatin + Short-term Sintilimab
Taxane and Carboplatin + Short-term Sintilimab is a approved stage product being developed by Innovent Biologics for Triple-negative Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05843292. Target conditions include Triple-negative Breast Cancer.
What happened to similar drugs?
0 of 6 similar drugs in Triple-negative Breast Cancer were approved
Approved (0) Terminated (0) Active (6)
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05843292 | Approved | Recruiting |
Competing Products
20 competing products in Triple-negative Breast Cancer